drugset / Trial / NCT00473486
Study in Patients With Advanced Non-Small Cell Lung Cancer Treated With Pemetrexed and Carboplatin Plus or Minus Sorafenib
Phase 1/2
Terminated
12 enrolled
University Hospital Muenster
Bayer · collabEli Lilly and Company · collab
RandomizedParallel-groupTriple-blindTreatment
Summary
The majority of patients with advanced NSCLC treated with standard platinum based chemotherapy regimens ultimately develop disease progression. Active therapies with improved toxicity profiles are clearly needed in this setting. The primary objective of this trial is to assess the toxicity profile and to determine the effect on progression free survival and time to progression in patients with advanced NSCLC treated with sorafenib in addition to carboplatin and pemetrexed.
Timeline
- Start
- 2007-05
- Primary completion
- 2008-08
- Completion
- 2010-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Sorafenib | Small molecule | 200 mg | Oral |
| Comparator | Sorafenib | Small molecule | 400 mg | Oral |
| Comparator | Carboplatin | Small molecule | — | Intravenous |
| Comparator | Pemetrexed | Small molecule | 500 mg/m2 | Intravenous |